ABC | Volume 112, Nº1, Janeiro 2019

Artigo Original Barros et al Alteração contrátil regional e cardiotoxicidade Arq Bras Cardiol. 2019; 112(1):50-56 1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48. 2. Hari KN, Benjamin F, Abigail MK, Theodore P, David H, Akinyemi B, et al. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics–related cardiac dysfunction. JACC Cardiovasc Imaging. 2016;9(10):1131-41. 3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-47. 4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. 5. Yeh ET, ChangH. Oncocardiology - past, present, and future. A review. JAMA Cardiol. 2016;1(9):1066-72. 6. López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies. Rev Esp Cardiol. 2017;70(6):487-95. 7. Meattini I, Curigliano G, Terziani F, Becherini C, Airoldi M, Allegrini G, et al. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without Trastuzumab. Med Oncol. 2017;34(5):75. 8. Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL. et al. Risk factors for anthracycline-associated cardiotoxicity. Support Care Cancer. 2016;24(5):2173- 80. 9. Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, BanachM. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factorreceptortype2–aprospectivestudy.ArchMedSci.2012;8(2):227-35 10. Kapusta L, Thijssen J, Groot-Loonen J, Antonius T, Mulder J, Daniëls O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000;26(7):1099-108. 11. Kapusta L, Groot-Loonen J, Thijssen J, de Graaf R, Daniëls O. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol. 2003;41(5):426-35. 12. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associate with adjuvant Trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014;5(4):154-66. 13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. 14. Nagueh SF, SmisethOA, Appleton CP, Byrd BF 3rd, DokainishH, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277- 314 15. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911- 39. 16. Singal P, Deally C,Weinberg L. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol. 1987;19(8):817-28. 17. De Beer E, Bottone A, Voest E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol. 2001;415(1):1-11. 18. Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induceearlychanges in leftventricularsystolicanddiastolic function:Asingle centre study. PLoS ONE. 2017;12(4):e0175544. 19. NegishiK,NegishiT,HareJL,HaluskaBA,PlanaJC,MarwickTH.Independent and incremental value of deformation indices for prediction of trastuzumab- induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493–8. 20. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603. 21. Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick T. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. 2014;63 (25 Pt A):2751-68. 22. Emren SV, Tuluce SY, Levent F, Tuluce K, Kalkan T, Alacacioğlu A, et al. Evaluation of Trastuzumab-induced early cardiac dysfunction using two dimensional Strain Echocardiography. MedUltrason. 2015;17(4):496-502. 23. Fei HW, Ali MT, Tan TC, Cheng KH, Salama L, Hua L, et al. Left ventricular global longitudinal strain in HER-2 + breast cancer patients treated with anthracyclines and trastuzumab who develop cardiotoxicity is associated with subsequent recovery of left ventricular ejection fraction. Echocardiography. 2016;33(4):519–26. 24. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9(1):184-8. 25. MarchandiseB,SchroederE,BoslyA,DoyenC,WeynantsP,KremerR,etal.Early detectionofdoxorubicincardiotoxicity:InterestofDopplerechocardiographic analysis of left ventricular filling dynamics. AmHeart J. 1989;118(1):92-8. 26. Lange SA, Ebner B, Wess A, Kogel M, Gajda M, Hitschold T, et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy. Clin Res Cardiol. 2012;101(6):415-26. 27. Cao L, Cai G, Chang C, Miao AY, Yu XL, Yang ZZ, et al. Diastolic dysfunction occurs early in her2-positive breast cancer patients treated concurrentlywith radiation therapy and trastuzumab. Oncologist. 2015;20(6):605-14. 28. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo- Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab- mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011;130(3):845-54. 29. Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales LJ, Moreno F, et al. Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. Oncologist. 2015;20(8): 864–72. 30. Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, Meekes MRA, de Haan AFJ, Tol J, et al. Does diastolic dysfunction precede systolic dysfunction in trastuzumab- induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol. 2016;23(4):824-32. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 56